Podcast 40: The CDMO/CMO Report: Parenteral Drugs 

Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org. 

Key topics: (see Chapter Markers in drop down menu in audio player above) 

  • Recent expansion projects (1:22) 
  • Baxter BioPharma Solutions (1:40) 
  • Curia (2:13) 
  • Vetter (3:28) 
  • Recipharm (5:06) 
  • WuXi STA (8:23) 
  • Jubilant HollisterStier (9:15) 
  • PCI Pharma Services (10:38) 
  • Grand River Aseptic Manufacturing (11:39) 
  • Catalent (13:12) 
  • Thermo Fisher Scientific (14:58) 
  • Lonza (15:36) 
  • Carbogen Amcis (17:01) 
  • Alcami (17:57) 
  • Delpharm (19:57) 
  • Fareva (20:52) 
  • WuXi Biologics (22:01) 
  • IDT Biologika (23:06) 
  • Emergent CDMO (23:42) 
  • BSP Pharmaceuticals (24:39) 
  • Aenova (25:33) 
  • Samsung Biologics (26:13)  
  • Ajinomoto Bio-Pharma Services (26:48) 
  • Selkirk Pharma (27:12) 
  • INCOG BioPharma Services (28:08) 
  • ten23 health (28:28) 
  • Berkshire Sterile Manufacturing (29:07) 

Links: 
Subscribe to our e-newsletter at www.dcatvci.org 
Follow us on Twitter @DCATvci 
Support the show